Yashima K, Litzky L A, Kaiser L, Rogers T, Lam S, Wistuba I I, Milchgrub S, Srivastava S, Piatyszek M A, Shay J W, Gazdar A F
Human Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas 75235-8593, USA.
Cancer Res. 1997 Jun 15;57(12):2373-7.
To investigate the role of telomerase in the multistage pathogenesis of lung cancer, we examined 205 fresh and archival tissue samples obtained from 40 patients, 34 of whom had invasive lung carcinoma, 5 with carcinoma in situ (CIS) without invasion, and 1 without lung carcinoma. We analyzed samples for telomerase enzyme activity using the semiquantitative PCR-based telomeric repeat amplification protocol assay (131 samples) or by a radioactive in situ hybridization method for expression of the RNA component of human telomerase (hTR; 74 samples). A subset of samples was assayed by both methods, and the correlation was excellent (30 of 36; 83%). With the exception of a carcinoid tumor and a necrotic squamous cell carcinoma, all tumor cells were moderate to strongly positive for both hTR and telomerase activity, except for foci of keratinization in squamous cell carcinomas. Telomerase positivity, with weak enzyme activity and/or low hTR expression, was present in basal epithelial cells of large bronchi, both histologically normal (26%) and hyperplastic (71%), and in 23% of peripheral lung samples (in epithelium of small bronchi and bronchioles or lymphoid aggregates). More advanced epithelial changes (metaplasia, dysplasia, and CIS) were associated with telomerase dysregulation. Dysregulation in preneoplasia was manifested in three ways: almost all such lesions expressed hTR, although enzyme activity levels were several-fold lower than in the corresponding invasive tumors; cells throughout these multilayered processes expressed hTR; and intense, focal up-regulation of hTR occurred in CIS foci in the vicinity of invasive cancers. Alveolar cells and areas of atypical adenomatous hyperplasia (possible precursor lesions for peripheral adenocarcinomas) were negative. Our studies demonstrate that dysregulation of telomerase occurs early in the multistage pathogenesis of bronchogenic lung carcinomas and that intense focal localized hTR expression in CIS may indicate imminent invasion.
为研究端粒酶在肺癌多阶段发病机制中的作用,我们检测了40例患者的205份新鲜组织样本和存档组织样本,其中34例患有浸润性肺癌,5例为无浸润的原位癌(CIS),1例无肺癌。我们使用基于半定量PCR的端粒重复序列扩增协议分析法(131份样本)或放射性原位杂交法分析样本中端粒酶的活性,以检测人端粒酶RNA成分(hTR;74份样本)的表达。一部分样本通过两种方法进行检测,相关性良好(36份中的30份;83%)。除类癌肿瘤和坏死性鳞状细胞癌外,所有肿瘤细胞的hTR和端粒酶活性均为中度至强阳性,但鳞状细胞癌中的角化灶除外。端粒酶阳性,酶活性弱和/或hTR表达低,存在于大体正常(26%)和增生(71%)的大气道基底上皮细胞中,以及23%的外周肺样本中(小支气管和细支气管上皮或淋巴样聚集处)。更高级别的上皮变化(化生、发育异常和CIS)与端粒酶失调有关。肿瘤前病变中的失调表现为三种方式:几乎所有此类病变均表达hTR,尽管酶活性水平比相应的浸润性肿瘤低几倍;这些多层病变中的细胞均表达hTR;在浸润性癌附近的CIS灶中,hTR出现强烈的局灶性上调。肺泡细胞和非典型腺瘤样增生区域(外周腺癌的可能前体病变)为阴性。我们的研究表明,端粒酶失调发生在支气管源性肺癌多阶段发病机制的早期,CIS中强烈的局灶性hTR表达可能表明即将发生浸润。